A new study at Montreal Heart Institute in Canada indicates that a new antioxidant drug shows benefits in the prevention and treatment of diabetes. Preliminary results on the drug, succinobucol, have been presented at medical meetings, but report say that more studies on cardiovascular risks needed.
Succinobucol is a chemical relative of probucol, a cholesterol-lowering drug taken off the market in the United States in 1995 because of side effects. In addition to its antioxidant effects, succinobucol also reduces inflammation.
During the trial, diabetes patients taking succinobucol provided better blood sugar control than not taking the drug. Atrial fibrillation, a dangerous heartbeat abnormality, was twice as likely to develop during the trial in those taking succinobucol. There was no difference in the incidence of death, cardiac arrest, heart attack, stroke or other cardiovascular endpoints between those taking or not taking the drug. The main side effect of the drug was diarrhea, reported by 23 percent of those taking it. One in seven of those reporting diarrhea stopped taking succinobucol.
The full study is published in the May 24 issue of The Lancet.
No User Responded In This Post
Leave Your Comments Here...